CU20130027A7 - Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales - Google Patents
Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionalesInfo
- Publication number
- CU20130027A7 CU20130027A7 CU2013000027A CU20130027A CU20130027A7 CU 20130027 A7 CU20130027 A7 CU 20130027A7 CU 2013000027 A CU2013000027 A CU 2013000027A CU 20130027 A CU20130027 A CU 20130027A CU 20130027 A7 CU20130027 A7 CU 20130027A7
- Authority
- CU
- Cuba
- Prior art keywords
- compounds
- salts
- alkyl
- diseases
- formula
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 5
- 108050001186 Chaperonin Cpn60 Proteins 0.000 title abstract 4
- 102000052603 Chaperonins Human genes 0.000 title abstract 4
- 239000000126 substance Substances 0.000 title abstract 4
- 230000002776 aggregation Effects 0.000 title 1
- 238000004220 aggregation Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 150000003839 salts Chemical class 0.000 abstract 4
- 239000000835 fiber Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 230000002265 prevention Effects 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 3
- 229940002612 prodrug Drugs 0.000 abstract 3
- 239000012453 solvate Substances 0.000 abstract 3
- 230000001225 therapeutic effect Effects 0.000 abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- -1 alkaline earth metal salts Chemical class 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 208000037259 Amyloid Plaque Diseases 0.000 abstract 1
- 241000469204 Mellita Species 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 abstract 1
- 125000005466 alkylenyl group Chemical group 0.000 abstract 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- TXWRERCHRDBNLG-UHFFFAOYSA-N cubane Chemical compound C12C3C4C1C1C4C3C12 TXWRERCHRDBNLG-UHFFFAOYSA-N 0.000 abstract 1
- 239000012990 dithiocarbamate Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 abstract 1
- 230000007935 neutral effect Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Esta invención se relaciona con la Química y la Bioquímica aplicadas al campo de la medicina y se refiere a un nuevo método de prevención y tratamiento terapéutico de las Enfermedades Conformacionales (EC),en particular a las enfermedades de origen amiloideo a través de la administración de una cantidad efectiva de uno o varios compuestos, sus sales, profármacos o solvatos, considerados en esta invención como chaperoninas químicas, de Fórmula I, En donde:R1: -alquilenil-C(O)NH-alquilenil-R4;R3: -COOH, -OH,-SH, -NH2, -alquil-NH, -alquil-N –ditiocarbamato de sales de metales alcalino-térreos, o sales de los grupos anteriormente relacionados, farmacéuticamente aceptables, para el tratamiento de enfermedades amiloidegénicas. R4: grupo succinimido; R2: -H,-alquil. El término ¨ alquil ¨ se refiere a cadenas alifáticas lineales o ramificadas de átomos de carbono saturados e hidrógenos, preferentemente de 1 a 4 átomos de carbono, comprendido entre los grupos metilo, etilo, n-propilo, iso-propilo, n- butilo o iso- butilo. El término ¨ alquilenil¨ se refiere a análogos divalentes de grupos alquílicos lineales o ramificados, preferentemente a radicales etinilo (-CH2CH2-) o butinilo (-CH2CH2CH2CH2-).Estos compuestos son neutros, lipofílicos y de bajo peso molecular.Los compuestos de la Fórmula I pueden ser convenientemente preparados como se describe en la patente Cubana No 2009-57, PCT-CU2010-000001,WO/2010/118706,EP 2 436 666 A20,y en las solicitudes de Patentes: México No 29/2011,Brasil:27/2011,EEUU 10/2012, Malasia 12/2012, Japón 9/2012,Canadá 7/2012,Sudáfrica 18/12012.La presente invención proporciona un nuevo método de prevención y tratamiento terapéutico de las EC, mediante la inhibición, reducción, desagregación de las estructuras prefibrilares, protofibrilas, fibras y placas amiloides, todas ellas caracterizadas por presentar estructuras tóxicas ß-cruzadas (ej. Enfermedad de Alzheimer (EA), Enfermedad de Parkinson (EP), Diabetes Mellitas Tipo 2(DM2),entre otras), a través de la administración de los compuestos de Fórmula I, considerados en esta invención como chaperoninas químicas, en cualquier composición farmacéutica aceptable de uno o varios compuestos o sus sales, profármaco o solvato, que son capaces de inhibir, reducir, eliminar, etcétera,la formación de estas estructuras que provocan un plegamiento anómalo de las proteínas, así como la desagregación de las fibras ya formadas. No tenemos conocimiento de que este método novedoso de prevención y tratamiento terapéutico de enfermedades conformacionales, a través de la modulación de la formación de estructuras tóxicas B cruzadas, prefibrilares, protofibrillas, fibras y placas, con la administración de uno o varios compuestos considerados como chaperoninas químicas, de fórmula I, en cualquier composición farmacéutica aceptable o sus sales, profármaco o solvato, haya sido descrito anteriormente.
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2013000027A CU20130027A7 (es) | 2013-02-28 | 2013-02-28 | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
| JP2015559419A JP6595345B2 (ja) | 2013-02-28 | 2013-12-30 | コンフォメーション病におけるβタンパク質凝集の新規の分子モジュレーターとしての化学シャペロニン |
| US14/771,144 US9763900B2 (en) | 2013-02-28 | 2013-12-30 | Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases |
| CA2904762A CA2904762C (en) | 2013-02-28 | 2013-12-30 | Chemical chaperonins as new molecular modulator of the beta protein aggregation in conformational disease |
| BR112015020777A BR112015020777A2 (pt) | 2013-02-28 | 2013-12-30 | Métodos para prevenir a formação de oligômeros solúveis, estruturas pré-fibrilares, protofibrilares e de fibra e placas amiloides, para redução de efeito citotóxicos de estruturas beta-enoveladas e para proteção e regeneração in vitro e/ou in vivo de células |
| PCT/CU2013/000009 WO2014131374A1 (es) | 2013-02-28 | 2013-12-30 | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
| ZA2015/06583A ZA201506583B (en) | 2013-02-28 | 2015-09-07 | Chemical chaperonins as novel molecular modulators of beta protein aggregation present in conformational diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU2013000027A CU20130027A7 (es) | 2013-02-28 | 2013-02-28 | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CU20130027A7 true CU20130027A7 (es) | 2014-10-30 |
Family
ID=50114254
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2013000027A CU20130027A7 (es) | 2013-02-28 | 2013-02-28 | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9763900B2 (es) |
| JP (1) | JP6595345B2 (es) |
| BR (1) | BR112015020777A2 (es) |
| CA (1) | CA2904762C (es) |
| CU (1) | CU20130027A7 (es) |
| WO (1) | WO2014131374A1 (es) |
| ZA (1) | ZA201506583B (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104311443B (zh) * | 2014-09-27 | 2016-03-09 | 张远强 | 一类含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
| CN104311444B (zh) * | 2014-09-27 | 2016-05-18 | 张远强 | 硝基取代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
| CN104311445B (zh) * | 2014-09-27 | 2016-04-13 | 张远强 | 含萘环的丁二酸酰胺衍生物、其制备方法及用途 |
| CN104311442B (zh) * | 2014-09-27 | 2016-04-06 | 张远强 | 卤代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
| CN104311441B (zh) * | 2014-09-27 | 2016-01-20 | 张远强 | 一类氯代萘环的丁二酸酰胺衍生物、其制备方法及用途 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| CU24720B1 (es) | 2020-11-24 | 2024-10-09 | Centro De Neurociencias De Cuba | Composición farmacéutica de derivados de naftaleno como agentes terapéuticos multiblancos para el tratamiento de la enfermedad de alzheimer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5276059A (en) | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
| SE9301831D0 (sv) | 1993-05-28 | 1993-05-28 | Analytecon S A | Pharmaceutical compositions |
| JP2711325B2 (ja) | 1993-06-14 | 1998-02-10 | 一彦 香味 | ポップアップルーフを有する自動車 |
| US6168776B1 (en) | 1994-07-19 | 2001-01-02 | University Of Pittsburgh | Alkyl, alkenyl and alkynyl Chrysamine G derivatives for the antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition |
| AU7664296A (en) * | 1995-11-02 | 1997-05-22 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
| DE19725619A1 (de) | 1997-06-17 | 1998-12-24 | Fraunhofer Ges Forschung | Peptide als Agonisten und/oder Inhibitoren der Amyloidbildung und Zytotoxizität sowie der Verwendung bei Alzheimer'schen Krankheit, beim Typ II Diabetes mellitus und bei spongiformen Encephalopathien |
| US5869469A (en) | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
| WO2001003680A2 (en) | 1999-07-09 | 2001-01-18 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| US20010047032A1 (en) | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| IT1317048B1 (it) | 2000-06-23 | 2003-05-26 | Sigma Tau Ind Farmaceuti | Uso dell'acido pamoico o di un suo derivato, o di un suo analogo, perla preparazione di un medicamento per il trattamento di patologie |
| DK1432453T3 (da) | 2001-08-27 | 2013-11-18 | Univ Pennsylvania | Stilbenderivater og anvendelse heraf til binding og billeddannelse af amyloid-plaques |
| WO2003063880A1 (en) | 2002-01-29 | 2003-08-07 | Protemix Corporation Limited | Disruption of islet amyloid by polycyclic compounds |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1603944A1 (en) | 2003-03-18 | 2005-12-14 | Applied Research Systems ARS Holding N.V. | Amylin aggregation inhibitors and use thereof |
| AR050865A1 (es) | 2004-09-09 | 2006-11-29 | Sanofi Aventis | Derivados de 2- morfolino-4-pirimidona |
| EP1841465A4 (en) | 2004-12-17 | 2009-04-01 | Univ Pennsylvania | STYLENE DERIVATIVES AND THEIR USE OF THE BINDING AND IMAGE DISPLAY OF AMYLOID PLAQUE |
| EA200801120A1 (ru) | 2005-10-18 | 2008-08-29 | Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. | Нафтильные производные в качестве ингибиторов агрегирования бета-амилоида |
| WO2010111870A1 (zh) | 2009-04-03 | 2010-10-07 | Xu Weixuan | 硬币自动识别分币装置 |
| CU23844B1 (es) | 2009-04-17 | 2012-10-15 | Ct De Neurociencias De Cuba | Procedimiento de obtención de nuevos derivados de naftaleno para el diagnóstico in vivo de la enfermedad de alzheimer |
-
2013
- 2013-02-28 CU CU2013000027A patent/CU20130027A7/es unknown
- 2013-12-30 CA CA2904762A patent/CA2904762C/en active Active
- 2013-12-30 WO PCT/CU2013/000009 patent/WO2014131374A1/es not_active Ceased
- 2013-12-30 JP JP2015559419A patent/JP6595345B2/ja not_active Expired - Fee Related
- 2013-12-30 US US14/771,144 patent/US9763900B2/en active Active
- 2013-12-30 BR BR112015020777A patent/BR112015020777A2/pt not_active IP Right Cessation
-
2015
- 2015-09-07 ZA ZA2015/06583A patent/ZA201506583B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP6595345B2 (ja) | 2019-10-23 |
| US20160106691A1 (en) | 2016-04-21 |
| WO2014131374A1 (es) | 2014-09-04 |
| US9763900B2 (en) | 2017-09-19 |
| ZA201506583B (en) | 2019-07-31 |
| BR112015020777A2 (pt) | 2017-08-22 |
| CA2904762A1 (en) | 2014-09-04 |
| JP2016510007A (ja) | 2016-04-04 |
| CA2904762C (en) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU20130027A7 (es) | Chaperoninas químicas como nuevos moduladores moleculares de la beta agregación proteica presente en las enfermedades conformacionales | |
| CY1124113T1 (el) | Συνθεσεις και μεθοδοι για την θεραπευτικη αντιμετωπιση διαταραχων κνς | |
| CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
| CR20110617A (es) | Derivados aminobutíricos sustituidos como inhibidores de neprilisina | |
| UY35273A (es) | Tiadiazol, análogos del mismo, y métodos para el tratamiento de condiciones relacionadas con defici encia de smn | |
| CR20110616A (es) | Derivados amino-propiónicos sustituidos como inhibidores de neprilisina | |
| ECSP16025201A (es) | Profármacos de amidas de piridona útiles como moduladores de canales de sodio | |
| MX2018000916A (es) | Derivados de benzodiazepina como inhibidores de rsv. | |
| BR112013017316A2 (pt) | compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd) | |
| AR100442A1 (es) | Derivados de pirido[1,2-a]pirimidin-4-ona para tratar atrofia muscular espinal | |
| BR112015000578A2 (pt) | moduladores da via do complemento e usos dos mesmos | |
| AR085004A1 (es) | Inhibidores selectivos de glicosidasas y usos de los mismos | |
| BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| DOP2014000008A (es) | 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk | |
| ECSP11011189A (es) | Moduladores de los receptores tipo toll | |
| DOP2007000079A (es) | Compuestos fenil amido heterocíclicos condensados | |
| UY38614A (es) | Derivados de benzodiazepinas como inhibidores del rsv | |
| UY31885A (es) | Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones. | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| AR097894A1 (es) | Inhibidores terapéuticos de cdk8 o uso de los mismos | |
| CO6531478A2 (es) | Derivados de etinilo | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| UY35209A (es) | Compuestos tricíclicos | |
| AR089122A1 (es) | Formulaciones orales para tratar la sobrecarga de metales |